BioCentury | Apr 27, 2018
Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and...
BC Week In Review | Feb 23, 2018
Financial News

Taiwan Liposome planning NASDAQ listing

Drug delivery company Taiwan Liposome Co. Ltd. (TPEx:4152) proposed to raise up to $50 million on Feb. 17 through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney...
BC Extra | Feb 20, 2018
Financial News

Taiwan Liposome planning NASDAQ listing

Taiwan Liposome Co. Ltd. (TPEx:4152) proposed to raise up to $50 million through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw. The company...
BC Week In Review | Jan 26, 2018
Company News

Taiwan Liposome forms JV with Jixi in China

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market Taiwan Liposome's drugs more efficiently in China. Jixi will invest $20 million to purchase a partial...
BC Extra | Jan 23, 2018
Company News

Taiwan Liposome forms marketing JV with Jixi

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market its drugs more efficiently in China. Jixi will invest $20 million to purchase a partial stake...
BC Week In Review | Jan 19, 2018
Clinical News

Matinas' MAT2203 meets in Phase IIa for mucocutaneous candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported data from three evaluable patients with chronic refractory mucocutaneous candidiasis in a Phase IIa trial showing that oral MAT2203 (CAmB) met the primary endpoint of reducing clinical symptoms. To...
BioCentury | Sep 9, 2017
Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
BC Innovations | Aug 24, 2017
Translation in Brief

The skinny on leishmaniasis

University of York scientists have shown skin, not just blood, is a major route by which Leishmania parasites spread from visceral leishmaniasis (VL) patients to the sand fly vector and back to a new host....
BC Innovations | Aug 24, 2017
Translation in Brief

Spit it out

The identification of ERK-5 as a brake on the process of macrophage vomocytosis not only provides new mechanistic insight into the poorly understood phenomenon but could lead to a strategy for preventing dissemination of fungal...
BC Week In Review | Jul 13, 2017
Clinical News

Matinas reports Phase II data of MAT2203 for vulvovaginal candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported top-line data from a Phase II trial to treat moderate to severe vulvovaginal candidiasis showing that oral CAmB (MAT2203) met the primary safety endpoint but missed the secondary efficacy...
Items per page:
1 - 10 of 444